Member Info for Bermudashorts

"This is a significant milestone, which further supports the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue. Biopsy is the current standard of care for men suspected of prostate cancer and yet 75% to 80% of men enduring a biopsy and running the risk of potentially serious complications, do not have prostate cancer. Less than 10% of biopsied patients have aggressive cancer where treatment is recommended. Aside from being non-invasive, Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients. We look forward to our continued work with Barts to progress the use of Parsortix in prostate cancer." http://www.investegate.co.uk/angle-plc--agl-/rns/barts-research-supports-potential-use-of-parsortix/201611040700052829O/

Interesting RNS and seems to be a pattern developing here. Another Swedish company with links to Karolinska Dev. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/co-development-agreement-with-asarina-ab/201611010700069182N/

Agreed

Karolinska have decided to continue with development of Dilaforette with a change of name to Modus Therapeutics and an IPO - I guess onto Nasdaq, Stockholm. Good stuff. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-notes-news-from-co-development-partner/201610240700082180N/

Thanks for that. Redx are lining up some exciting products and will be good to see some of them make it into the clinic. These trials obviously need funding and it would be good to get that out of the way.

Really interesting RNS this morning. "The RNA analysis of cancer cells offers the opportunity to stratify patients into phenotypical subgroups according to their expression profiles, providing an important framework for therapeutic decisions, including determining which drugs will be effective for which patient, based on a simple blood test." http://www.investegate.co.uk/angle-plc--agl-/rns/research-published-in-clinical-chemistry/201609300700092625L/

True but they are chalk and cheese in terms of business model, scale, strategy, etc. Are you invested here? Worth noting that REDX are part of the IMI consortium, led by GlaxoSmithKline and Sanofi - this is a European initiative to to advance the development of potential antibiotics against Gram-negative bacteria. REDX now have in vivo proof of concept and it will be interesting to see what they do with it once they have selected their lead candidate.

lol - the RNS is announcing further pre-clinical work on bacterial topoisomerase inhibitor compounds, the operative word being pre-clinical. They have no choice but to use terms such as possible, has the potential etc. - it's standard language for drugs at this stage of development. This is the important part of the RNS:- "In the pre-clinical study, Redx achieved a significant decrease in bacterial infection levels against a multi-drug resistant Gram-negative bacterial strain when compared with tigecycline, a current drug-of-last-resort used in treating antibiotic resistant bacteria." Still a long way to go of course and as ever with biotech (and especially so here given the scale of REDX) the risks are whether funding will be available to take the compounds further and whether or not those compounds will be as effective when they get into the clinic. On the plus side there is a global movement to combat antibiotic resistance, the market is huge and funding may not be as much of an issue as in other fields of medicine.

Excellent news - "Redx, the drug development company, announces the discovery of a series of compounds that have the potential to create the first novel class of broad-spectrum antibiotics in 30 years." http://www.investegate.co.uk/redx-pharma-plc--redx-/rns/discovery-of-breakthrough-antibiotic-compounds/201609270700118675K/

Interims released today:- - Strong first half financial performance - revenues up 21% and gross profit up 26% - £19 million new contracts signed resulting in a backlog of £60 million Revenue growth seems largely down to Primevigilance http://www.investegate.co.uk/ergomed-plc--ergo-/rns/half-year-report/201609260700097528K/

Pontil - glad you're still here. Yes interesting to see the movement - 48p to around 62p in just over a week. Let's hope it continues!! All good things and all that............

http://www.investegate.co.uk/ergomed-plc--ergo-/rns/contract-win-validates-rationale-of-acquisitions/201609220700134981K/

Presenting at ShareSoc seminar next week http://www.sharesoc.org/altrinchamseminar.html

Interesting RNS this morning and of course finding the best anti PD-1 combination therapy is a hotly contested area at the moment, especially following Bristol-Myers Squibb's recent phase III trial failure for Opdivo in lung cancer. Would have been nice to see some figures around the findings - perhaps they'll be presenting them at a conference at some stage. http://www.investegate.co.uk/redx-pharma-plc--redx-/rns/re--porcupine-inhibitor-and-cancer-immunotherapy/201609190700101362K/

lol http://www.investegate.co.uk/venn-life-sciences--venn-/rns/directorate-change/201609130700096049J/

http://www.vennlifesciences.com/appointment-of-chairman/

http://www.investorschronicle.co.uk/2016/09/08/shares/directors-deals/frenkel-topping-chairman-ups-his-stake-5EFKsOdoUYCFk0ips2ALCK/article.html

For anyone who is interested in a closer look at the Parsortix System the link below is to a training video https://vimeo.com/181762900

Good stuff http://www.investegate.co.uk/ergomed-plc/ergo/recruitment-completed-in-phase-iia-clinical-trial/201609080700102253J/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Ergomed plc%20Alert

Link to abstract below (page 15, Abstract No. 42) https://www.aacc.org/~/media/files/annual-meeting/2016/abstracts/aacc16_am_a001a062.pdf?la=en